REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Clinical trials for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy offers hope for patients with relapsed T-Cell lymphoma
Disease control OngoingThis study tests a combination of two drugs, pembrolizumab (an immunotherapy that helps the immune system attack cancer) and romidepsin (a drug that blocks enzymes cancer cells need to grow), in people with peripheral T-cell lymphoma that has come back or stopped responding to tr…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 15, 2026 11:53 UTC
-
Virus-Immunotherapy combo targets tough skin cancers
Disease control OngoingThis study tests a two-step treatment for people with rare skin cancers or certain lymphomas that haven't improved with standard care. First, patients receive a virus-based drug (talimogene laherparepvec) injected into tumors to help the immune system recognize and attack cancer …
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 11, 2026 20:47 UTC
-
New drug duo takes on tough lymphomas
Disease control OngoingThis early-stage trial is testing a combination of two drugs, tazemetostat and belinostat, for people with lymphoma that has returned or stopped responding to standard treatments. The main goals are to find the safest dose and to see if the combination can shrink tumors. About 48…
Matched conditions: REFRACTORY PRIMARY CUTANEOUS T-CELL NON-HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 04, 2026 16:19 UTC